dromlakhani Discuss fertility-preserving strategies before testosterone therapy in men after anabolic steroids or under TTh
STEP 1 — Gather Information
Collect history of anabolic‑steroid use (type, duration, timing) or current testosterone therapy formulation and dose, assess desire for future paternity, obtain baseline total testosterone, LH, FSH, estradiol, and if available semen analysis and testicular volume; note any comorbidities that affect fertility.
STEP 2 — Rule In / Rule Out
Determine whether the patient desires fertility preservation: Yes → proceed to classification; No → initiate testosterone therapy after shared decision‑making and monitor standard parameters.
STEP 3 — Classify or Stratify
Stratify by exposure: recent AAS cessation → consider hCG monotherapy or hCG + FSH; long‑term prescribed TTh → consider hCG ± FSH, SERM (clomiphene/enclomiphene), aromatase inhibitor, or intranasal testosterone; severe hypogonadism with low LH/FSH → add recombinant FSH; mild suppression → hCG alone may suffice.
STEP 4 — Decide
Initiate the selected fertility‑preserving regimen, fully discuss its off‑label nature, expected timeline for spermatogenesis recovery (3‑24 months), and schedule follow‑up with total testosterone, LH/FSH, estradiol, and semen analysis every 4‑6 months; adjust dose based on response.
Clinical Guardrails / Mimics / Pitfalls
Do not start testosterone therapy without documenting the fertility discussion; avoid assuming spontaneous recovery after TTh cessation; do not use testosterone monotherapy to preserve fertility; avoid unmonitored off‑label drug use; do not ignore patient’s paternity goals when they exist.
Concrete Clinical Example
A 28‑year‑old male bodybuilder discontinued AAS 2 months ago, presents with low libido and total testosterone 8 nmol/L, wishes to father children in the future. Clinician discusses hCG monotherapy, starts hCG 1500 IU subcutaneously twice weekly, orders semen analysis and hormone panel at 3 months to assess spermatogenesis recovery before considering any testosterone therapy.
Source: Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024), ICSM Panel, 2025, DOI: 10.1093/sxmrev/qeaf036